Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy
Copyright © 2023 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc..
PURPOSE: Review the historical context of research and changing therapeutic landscape of thyroid-associated ophthalmopathy (TAO) by focusing on the relationship between TAO, CD34+ fibrocytes, thyrotropin receptor (TSHR), and insulin-like growth factor-I receptor (IGF-IR).
METHODS: A literature review using search terms, including fibrocytes, IGF-IR, TSHR, TAO, and thyroid eye disease.
RESULTS: The mechanisms involved in TAO have been partially identified. Substantial progress has been made over several decades, including 1) recognizing the interplay between the professional immune system and orbital tissues; 2) TSHR and IGF-IR act interdependently in mediating the pathogenesis of TAO; 3) Multiple cytokines and specific immune cells are involved in activating and remodeling orbital tissue; 4) Recognition of these mechanisms is allowing the development of target therapies such as teprotumumab, a monoclonal antibody IGF-IR inhibitor approved by the US Food and drug administration for treatment of TAO; and 5) It appears that teprotumumab acts on the systemic immune system peripheral to the orbit.
CONCLUSION: Additional molecules targeting IGF-IR and other plausible disease mechanisms are currently under development. This activity in the TAO therapeutic space portends even greater improvements in patient care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Ophthalmic plastic and reconstructive surgery - 39(2023), 6S vom: 01. Dez., Seite S9-S18 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smith, Terry J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 07.12.2023 Date Revised 08.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/IOP.0000000000002509 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365458988 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365458988 | ||
| 003 | DE-627 | ||
| 005 | 20240208231938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/IOP.0000000000002509 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1284.xml |
| 035 | |a (DE-627)NLM365458988 | ||
| 035 | |a (NLM)38054981 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smith, Terry J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2023 | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc. | ||
| 520 | |a PURPOSE: Review the historical context of research and changing therapeutic landscape of thyroid-associated ophthalmopathy (TAO) by focusing on the relationship between TAO, CD34+ fibrocytes, thyrotropin receptor (TSHR), and insulin-like growth factor-I receptor (IGF-IR) | ||
| 520 | |a METHODS: A literature review using search terms, including fibrocytes, IGF-IR, TSHR, TAO, and thyroid eye disease | ||
| 520 | |a RESULTS: The mechanisms involved in TAO have been partially identified. Substantial progress has been made over several decades, including 1) recognizing the interplay between the professional immune system and orbital tissues; 2) TSHR and IGF-IR act interdependently in mediating the pathogenesis of TAO; 3) Multiple cytokines and specific immune cells are involved in activating and remodeling orbital tissue; 4) Recognition of these mechanisms is allowing the development of target therapies such as teprotumumab, a monoclonal antibody IGF-IR inhibitor approved by the US Food and drug administration for treatment of TAO; and 5) It appears that teprotumumab acts on the systemic immune system peripheral to the orbit | ||
| 520 | |a CONCLUSION: Additional molecules targeting IGF-IR and other plausible disease mechanisms are currently under development. This activity in the TAO therapeutic space portends even greater improvements in patient care | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Receptors, Thyrotropin |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Ophthalmic plastic and reconstructive surgery |d 1993 |g 39(2023), 6S vom: 01. Dez., Seite S9-S18 |w (DE-627)NLM013070444 |x 1537-2677 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2023 |g number:6S |g day:01 |g month:12 |g pages:S9-S18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/IOP.0000000000002509 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2023 |e 6S |b 01 |c 12 |h S9-S18 | ||